Dexcom's glucose monitor use shows benefit in non-insulin diabetic patients in study - Reuters
Dexcom's glucose monitor use shows benefit in non-insulin diabetic patients in study Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Key People
No people linked to this story
Locations
All Coverage
<a href="https://news.google.com/rss/articles/CBMi4wFBVV95cUxOLU1uNzJsNDVWUmN1UHVSalZqUGt3Z0lULXZpTkJjamVfVWQ1bU9qRmtCMzBHVkFTYVlqbXUwNHR5REd6T1lybmRsNV96T1hiQXdjWnV3X1ZNdnR6c2RUTEp2NGdueHJIOVFNVi1tamdOU2w2S1VfbFlPYzVfSlR5RW5aX0loMVBnbHJSZ2dTVGY5MUE5dzR2QWp2VTBvZVVZRXFVZHFrTW5mSlo3R1BXS0ZFUUJMUlRReGk1MGwwNXFrLWJ3WDRqSFhQb1JSelBmbnp5Q2Z6d29hWWZPVTlNU2toRQ?oc=5" target="_blank">Dexcom's glucose monitor use shows benefit in non-insulin diabetic patients in study</a> <font color="#6f6f6f">Reuters</font>
Similar Stories
Related coverage based on topic and tags
US FDA approves Bristol Myers' blood cancer treatment - Reuters
US FDA approves Bristol Myers' blood cancer treatment Reuters
August 13, 2026 at 09:33 PMCapricor shares skyrocket as FDA agrees to review new Duchenne drug data - Reuters
Capricor shares skyrocket as FDA agrees to review new Duchenne drug data Reuters
August 14, 2026 at 10:41 AMUS FDA approves Regeneron's rare bone disorder drug - Reuters
US FDA approves Regeneron's rare bone disorder drug Reuters
August 19, 2026 at 06:53 PMVIEW Moderna-Merck melanoma vaccine data boosts outlook, but analysts await full results - Reuters
VIEW Moderna-Merck melanoma vaccine data boosts outlook, but analysts await full results Reuters
August 19, 2026 at 02:45 PMNovo CEO says obesity market won't be winner-take-all battle with Lilly - reuters.com
Novo CEO says obesity market won't be winner-take-all battle with Lilly reuters.com
August 13, 2026 at 10:02 AMNovo begins study to find lowest effective dose for Wegovy pill - Reuters
Novo begins study to find lowest effective dose for Wegovy pill Reuters
August 19, 2026 at 03:26 PM